MME and AL amyloidosis: This has important implications both for clinical trials, where their inclusion may negate the beneficial effect of the intervention (as cited in the recent prospective comparison of angiotensin receptor-neprilysin inhibitor with angiotensin-receptor blockers Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial [30]), and clinical management, where specific therapies are available (e.g. light-chain amyloidosis).